Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 5/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13075463 | 0.78 | THRB (0.35) | L3MBTL1THRBTGFBR1MAPK14 | |
| SCHEMBL24744542 | 0.75 | THRB (0.33) | THRBTGFBR1MAPK14 | |
| SCHEMBL13684196 | 0.72 | MEN1 (0.32) | POLBTHRBTGFBR1MAPK14KMT2A | |
| SCHEMBL26340803 | 0.72 | THRB (0.32) | THRBTGFBR1MAPK14 | |
| SCHEMBL26937985 | 0.72 | KDM5B (0.33) | THRBTGFBR1MAPK14 | |
| SCHEMBL16920699 | 0.71 | MEN1 (0.35) | POLBTHRBTGFBR1KMT2A | |
| SCHEMBL21315234 | 0.71 | — | — | |
| SCHEMBL24745361 | 0.71 | LMNA (0.44) | POLBLMNAKMT2A | |
| SCHEMBL6105067 | 0.69 | PRMT1 (0.39) | KMT2A | |
| SCHEMBL38665339 | 0.69 | ALDH1A1 (0.32) | THRBTGFBR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2424843-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | Novartis AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | L3MBTL1 478/4885POLB 1961/4885THRB 3761/4885 |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | L3MBTL1 3815/4885POLB 798/4885THRB 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.